论文部分内容阅读
目的:对吡非尼酮的抗纤维化作用和临床应用进行探讨。方法:收集发表的相关文章,对吡非尼酮的药物代谢动力学、药理作用、临床试验和真实世界研究进行分析总结。结果:吡非尼酮是一种新型小分子化合物,具有抗纤维化、抗炎和抗氧化作用。在动物实验中,它能够抑制促纤维化因子包括转化生长因子-β的表达,减少成纤维细胞增殖和胶原沉积;同时抑制多种炎性因子释放,减轻炎症反应;通过清除自由基、抑制脂质过氧化反应,减轻氧化应激。临床试验和真实世界研究均表明,吡非尼酮可以减少特发性肺纤维化(IPF)患者的肺功能下降、延缓疾病进展。结论:吡非尼酮具有广谱抗纤维化作用,轻中度IPF患者服用吡非尼酮能获益。
Objective: To investigate the antifibrotic effect and clinical application of pirfenidone. METHODS: The published articles were collected and the pharmacokinetics, pharmacological effects, clinical trials and real-world studies of pirfenidone were summarized. Results: Pirfenidone is a novel small molecule compound with anti-fibrosis, anti-inflammatory and anti-oxidation effects. In animal experiments, it can inhibit the expression of pro-fibrotic factors including transforming growth factor-β, reduce fibroblast proliferation and collagen deposition; while inhibiting the release of a variety of inflammatory cytokines, reduce inflammation; by eliminating free radicals, inhibition of lipid Peroxidation, reduce oxidative stress. Clinical trials and real-world studies have shown that pirfenidone reduces lung function and delays disease progression in patients with idiopathic pulmonary fibrosis (IPF). CONCLUSIONS: Pfinalnid has a broad spectrum of antifibrotic effects and is beneficial in patients with mild to moderate IPF when taking pirfenidone.